HIK.L

Hikma Pharmaceuticals Plc
Hikma Pharmaceutical - Block listing Interim Review
1st October 2024, 08:45
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4469G
Hikma Pharmaceuticals Plc
01 October 2024
 

Hikma Pharmaceuticals PLC

Block Listing Six Monthly Return

 

Date: 1 October 2024

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("MIP") and Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP") (together "the Plans")

Period of return

From: 1 April 2024

To:

30 September 2024

Balance of unallotted securities under scheme(s) from previous return:

The Plans: 312,624 Ordinary Shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

The Plans: 0 Ordinary Shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

MIP: 1,194 Ordinary Shares of 10 pence

EIP: 0 Ordinary Shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

The Plans: 311,430 Ordinary Shares of 10 pence

 

Name of contact:

Helen Middlemist

Telephone number of contact:

+44(0)20 7399 2760

 

 

 

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUPGWCUUPCURG]]>
TwitterFacebookLinkedIn